Oral Glucose Tolerance Test (OGTT) Metrics Surpass Continuous Glucose Monitoring Data for T1D Prediction in Multiple-Autoantibody–Positive Individuals
An erratum to this article was published (J Clin Endocrinol Metab, 18 Jan 2024 ↗)
Authors' conclusion
Every 6-month CGM measures in multiple-AAB-positive individuals are predictive of subsequent T1D, but less so than OGTT-derived variables. CGM may have feasibility advantages and be useful in some settings. However, our data suggest there is insufficient evidence to replace OGTT measures with CGM in the context of clinical trials.
Study context
- Population
- Multiple-AAB-positive relatives in the TrialNet Pathway to Prevention (TN01) continuous glucose monitoring (CGM) ancillary study
- Participants
- 93 relatives
- Comparison
- CGM vs OGTT-based metrics for prediction of T1D
- Outcome
- Prediction of T1D diagnosis (ROC AUC of CGM and OGTT metrics)
Methodological detailsCGM ancillary study of TrialNet Pathway to Prevention (TN01), academic centers
- CGM ancillary study of TrialNet Pathway to Prevention (TN01)
- Academic centers
Performance
As reported in the abstract
Prediction of T1D (ROC AUC)
| Test or model | AUC of individual CGM values | AUC of highest-ranking metrics (4/7) |
|---|---|---|
| CGM | 50% to 69% | — not stated in the abstract |
| OGTT | — not stated in the abstract | ∼80% |
AUC of individual CGM values
CGM50% to 69%
OGTT— not stated in the abstract
AUC of highest-ranking metrics (4/7)
CGM— not stated in the abstract
OGTT∼80%
— not stated in the abstract
Further findings
Metrics differing between those who did or did not develop T1D
- OGTT metrics differing
- 5 of 7
- CGM metrics differing
- 29/48
- HbA1c did not differ
Original publication
OGTT Metrics Surpass Continuous Glucose Monitoring Data for T1D Prediction in Multiple-Autoantibody–Positive Individuals. J Clin Endocrinol Metab. Published 13 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →